Abivax Shares Soar 15% Mid-Session After a 1,414% Annual Surge
Abivax stock has climbed 15.05% this Wednesday, December 10, reaching €120.80 by midday, up from a close of €105 the previous day. This latest increase pushes the stock to a record high and extends an exceptional trend that has seen its annual performance soar to 1,414%, making the French biotech the top performer in the Stoxx 600 for 2025.
Record Performance and Market Dynamics
Abivax's stock has gained 18.9% over the week, erasing losses recorded at the beginning of December and confirming the strength of the upward trend. The quarterly performance has reached 58.12%, illustrating an acceleration of movement since the reported patient outcomes from the ABTECT trials in early November. This momentum is part of a broader fundamental revaluation of the stock since the announcement in July of positive phase 3 results, which triggered a more than fourteen-fold increase in the company's market valuation.
Market Enthusiasm and Acquisition Rumors
Market enthusiasm for Abivax is based on significant clinical advancements of obefazimod, its drug candidate for the treatment of ulcerative colitis. However, it is particularly a rumor of a potential acquisition by Eli Lilly, a giant in the American pharmaceutical sector, that has spurred the stock's surge. Currently, these speculations are unconfirmed.
Technical Analysis and Future Outlook
Technically, the price of €120.80 is significantly above the 50-day moving average positioned at €89.27, confirming a decidedly bullish underlying trend. The even more pronounced gap with the 200-day moving average at €41.83 illustrates the magnitude of the transformation since the beginning of the year. The RSI at 57 remains in a neutral zone, suggesting that the stock still has room for growth before reaching an overbought zone, a technically favorable signal for the continuation of the movement. Bollinger Bands frame the stock between a support at €87.55 and a resistance at €114.63, with the price having crossed the upper boundary of this channel, indicating an acceleration of momentum. This indicator signals an extension of volatility characteristic of a bullish expansion phase. The major resistance identified at €111.80 has been clearly breached, paving the way for new highs. With a negative beta of -0.05, Abivax shows a complete decoupling from the CAC 40, explaining its ability to progress independently in an uncertain market environment. The one-month volatility of 18.82% reflects the significant fluctuations inherent in biotechnological values in advanced clinical trial phases, yet this characteristic does not diminish investor confidence in the commercial transformation potential of the drug candidate.
